Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ASP within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 10, 2020 07:00 ET
Acerus Provides Update on NATESTO® Approval Process in Europe
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that the dossier filed as a Decentralized Procedure in 19 European countries for the approval of NATESTO® has been withdrawn. The regulatory dossier was filed by our European licensee - medac Gesellschaft für klinische Spezialpräparate mbH (“medac”).
Read full article
Dec 18, 2019 07:00 ET
Acerus Announces Closing of Additional US$6.5 Million Financing From First Generation Capital
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it has closed the previously announced amendment and restatement of the US$5.0 million subordinated secured term loan facility previously entered into on July 19, 2019 between Acerus and First Generation Capital, Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus, to (i) increase the borrowed amount to US$11.5 million, (ii) extend the maturity date to June 30, 2021 and (iii) cap the total amount of interest payable to First Generation und
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.56
--
--
Price to Sales - TTM
2.81
4.17
8.84
Price to Book - most recent quarter
--
2.07
2.23
Price to Cash Flow per share - TTM
--
11.74
10.69
Price to Free Cash Flow per share - TTM
--
13.53
16.64
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 15, 202066,925-31,225
Dec 31, 201998,15057,069
Dec 15, 201941,081-9,510
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause. The Company offers Natesto, which is the testosterone nasal gel in the United States for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The Company offers TEFINA, which is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction. The Company focuses on TriVair Deposition/Dispersion System, which is a unit dose dry powder inhaler and nasal dispersion system.

See business summary

Twitter

Search (past week) for $ASP.CA

  • No tweets found